Pennsylvania is currently home to 3474 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Philadelphia, Pittsburgh, Hershey and Allentown. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Imipenem/Cilastatin/Relebactam Pharmacokinetics, Safety, and Outcomes in Adults and Adolescents With Cystic Fibrosis
NCT05561764
Recruiting
There is established evidence that patients with Cystic Fibrosis (CF) may have altered antibiotic pharmacokinetics compared with non-CF patients. Imipenem/cilastatin/relebactam is a novel broad spectrum intravenous beta-lactam/beta-lactamase inhibitor combination antibiotic with potent activity against multidrug resistant Gram-negative bacteria, including imipenem non-susceptible Pseudomonas aeruginosa. Relebactam has also been shown to restore imipenem activity in Burkholderia cepacia complex,... Read More
Gender:
All
Ages:
12 years and above
Trial Updated:
01/03/2023
Locations: St. Christopher's Hospital for Children, Philadelphia, Pennsylvania
Conditions: Cystic Fibrosis, Pneumonia, Bacterial
Register for Updates
Cefiderocol Pharmacokinetics in Adult Patients With Cystic Fibrosis
NCT05314764
Recruiting
There is established evidence that adult patients with Cystic Fibrosis (CF) may have altered antibiotic pharmacokinetics compared with non-CF patients. Cefiderocol is a newly approved broad spectrum intravenous siderophore cephalosporin antibiotic, which has potent in vitro activity against multidrug resistant Pseudomonas aeruginosa, Burkholderia cepacia complex, Achromobacter species, and Stenotrophomonas maltophilia, all pathogens implicated in CF pulmonary exacerbations. This study will deter... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
12/22/2022
Locations: UPMC Presbyterian Hospital, Pittsburgh, Pennsylvania
Conditions: Cystic Fibrosis, Pneumonia, Bacterial
Register for Updates
Study in Patients Undergoing Debridement, Antibiotics, and Implant Retention (DAIR) for Treatment of a Periprosthetic Joint Infection (PJI) Occurring After Total Knee Arthroplasty (TKA)
NCT05137314
Recruiting
The purpose of this study is to learn about the safety and effects of PLG0206 for treating periprosthetic joint infections (PJI) in conjunction with the DAIR (debridement, antibiotics and implant retention) surgical procedure for patients with periprosthetic joint infections (PJI) after total knee arthroplasty (TKA) .
Gender:
All
Ages:
Between 18 years and 79 years
Trial Updated:
12/21/2022
Locations: Rothman, Philadelphia, Pennsylvania
Conditions: Joint Infection
Register for Updates
Dose Escalation and Dose Expansion Study of CPO-100 in Patients With Advanced Solid Tumors
NCT04931823
Recruiting
This is a Phase 1, multicenter, open-label, dose escalation and dose expansion study to evaluate the safety, tolerability, pharmacokinetics, and preliminary evidence of antitumor activity of CPO-100 administered intravenously in cycles of 3 weekly doses with 1 week rest (1 cycle = 4 weeks) in adult patients with advanced solid tumors.
Gender:
All
Ages:
18 years and above
Trial Updated:
12/16/2022
Locations: University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania
Conditions: Solid Tumor
Register for Updates
A Study of TSR-022 in Participants With Advanced Solid Tumors (AMBER)
NCT02817633
Recruiting
This is a first-in-human study evaluating the anti-T cell immunoglobulin and mucin containing protein-3 (TIM-3) antibody TSR-022. The study will be conducted in 2 parts with Part 1 consisting of dose escalation and Part 2 dose expansion. Part 1 will determine the recommended Phase 2 dose (RP2D) of TSR-022 and Part 2 will evaluate the antitumor activity of TSR-022 in combination with TSR-042 or docetaxel and as monotherapy
Gender:
All
Ages:
18 years and above
Trial Updated:
12/09/2022
Locations: GSK Investigational Site, Bethlehem, Pennsylvania
Conditions: Neoplasms
Register for Updates
A Study to Evaluate EDP-235 in Non-hospitalized Adults With COVID-19
NCT05616728
Recruiting
Study of EDP-235 in Non-hospitalized Adults with Mild or Moderate COVID-19.
Gender:
All
Ages:
Between 18 years and 64 years
Trial Updated:
12/06/2022
Locations: Frontier Clinical Research, LLC, Smithfield, Pennsylvania
Conditions: COVID-19
Register for Updates
Knee Related Subchondral Bone Lesions Treated With IOBP
NCT05314608
Recruiting
The study will be a prospective, multicenter clinical study evaluating clinical and patient reported outcome measures of subjects receiving IOBP® surgical technique using Angel cPRP and BMA processing system to treat subchondral bone pathology (SBP).
Gender:
All
Ages:
Between 18 years and 60 years
Trial Updated:
12/02/2022
Locations: Allegheny-Singer Research Institute, Pittsburgh, Pennsylvania
Conditions: Subchondral Cyst
Register for Updates
Evaluate F901318 Treatment of Invasive Fungal Infections in Patients Lacking Treatment Options
NCT03583164
Recruiting
A study to evaluate F901318 (study drug) for the treatment of invasive fungal infections in patients lacking suitable alternative treatment options.
Gender:
All
Ages:
16 years and above
Trial Updated:
11/30/2022
Locations: UPMC, Pittsburgh, Pennsylvania
Conditions: Invasive Fungal Infections
Register for Updates
A Pivotal Study of Safety and Effectiveness of NanoKnife IRE for Stage 3 Pancreatic Cancer
NCT03899636
Recruiting
Subjects will be offered the opportunity to participate in a randomized, controlled, 2-arm, unblinded multicenter trial (RCT). There will be 2 study arms: the control arm receiving chemotherapy with the modified FOLFIRINOX regimen alone; and the irreversible electroporation (IRE) arm, receiving chemotherapy with the modified FOLFIRINOX regimen followed by IRE with the NanoKnife System using either an open or a percutaneous approach. All subjects will be treated with the modified FOLFIRINOX regim... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
11/23/2022
Locations: St. Luke's Cancer Center, Easton, Pennsylvania
Conditions: Stage III Pancreatic Cancer
Register for Updates
MEASuRE: Metreleptin Effectiveness And Safety Registry
NCT02325674
Recruiting
The study is a post-authorization, prospective, voluntary registry of patients treated with commercial metreleptin including, but not limited to, patients in the US and EEA.
Gender:
All
Ages:
All
Trial Updated:
11/23/2022
Locations: Children's Hospital of Philadelphia, Philadelphia, Pennsylvania
Conditions: Generalised Lipodystrophy, Partial Lipodystrophy
Register for Updates
Two Year Developmental Follow-up for PREMOD2 Trial (Premature Infants Receiving Milking or Delayed Cord Clamping)
NCT03476980
Recruiting
An extension of the PREMOD2 trial, the PREMOD2 Follow-Up trial will evaluate the neurodevelopmental outcomes at 22-26 months corrected age of preterm children who received UCM or DCC. This prospective multi-national randomized controlled trial (RCT) is a two-arm parallel non-inferiority design of two alternative approaches of treatment.
Gender:
All
Ages:
Between 22 months and 42 months
Trial Updated:
11/22/2022
Locations: Magee-Womens Hospital, Pittsburgh, Pennsylvania
Conditions: Neurodevelopmental Abnormality
Register for Updates
TruGraf® Long-term Clinical Outcomes Study
NCT04491552
Recruiting
This is a prospective, multi-center, observational study. Subjects will have OmniGraf™ (TruGraf® and TRAC™) testing at study enrollment and thereafter every 3 months. In addition subjects will have OmniGraf™ (TruGraf® and TRAC™) testing at any time there is a clinical suspicion of acute rejection. Data collection for the primary objective extends over a 2-year period.
Gender:
All
Ages:
18 years and above
Trial Updated:
11/10/2022
Locations: Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania
Conditions: Kidney Transplant Rejection
Register for Updates